Document is current

Article History

Received: 1 October 2020

Accepted: 15 December 2020

First Online: 22 January 2021

Ethics approval and consent to participate

: The study is registered at (number NCT00680992) and was performed at 30 sites in 12 countries. The study was approved by each site’s independent ethics committee, and all patients provided written informed consent.

: Not applicable

: Dr. Palmerini has served on advisory boards for Amgen, Daiichi Sankyo, Lilly, EUSA Pharma, and Deciphera; has received other research support from Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, and PharmaMar; and has received travel support from Lilly, PharmaMar, and Takeda.Dr. Seeger reports nothing to disclose.Drs. Gambarotti, Righi, and Picci received institutional funding from Amgen for clinical and pathological input and revision of the cases reported in this study.Dr. Reichardt has received personal fees from Novartis, Pfizer, Bayer, PharmaMar, Clinigen, Lilly, Deciphera, Merck, Roche, and Amgen Inc.Dr. Bukata has served as a consultant for Amgen and Radius, speakers’s bureau for Radius, and board service for the Orthopaedic Research Society and the US National Osteoporosis Foundation.Dr. Blay has received research grants and honoraria from Novartis and Amgen Inc.Drs. Dai and Jandial are employed by and own stock in Amgen Inc.